Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Vytora Health

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Vytora Health head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 10 · Grade B+

Vytora Health

Visit Vytora Health Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 87 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make Vytora Health a bad call — it's best for readers who want a legitscript-certified desk that can also route to brand-name glp-1s — without paying a premium for it. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
85
Supply Reliability
95
87
Transparency
90
88
Access Breadth
93
90
Clinical Oversight
92
88
Track Record
88
82
CoreAge RxBrief Score 94 · 87Vytora Health

Price, coverage & the tracker

CoreAge RxVytora Health
Brief Score94/100 (A)87/100 (B+)
Semaglutide$149/mo$150/mo
Tirzepatide$349/mo$200/mo
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableStableprice stable

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

Vytora Health: $150 sema / $200 tirz nationwide; LegitScript-certified with brand-name access.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.